Drug Trial Radar · NCT05102006
A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors
Last checked: Nov 19, 2026Latest source record: Jun 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Nov 30, 2021
Primary completion
May 22, 2024
Study completion May 22, 2024
Sponsor
- Lead sponsor
- Nanjing Leads Biolabs Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, open-label, multicenter Phase Ib/II clinical study to evaluate the safety, tolerability, PK characteristics, immunogenicity and efficacy of LBL-007 in combination with Toripalimab in Treatment of Advanced Malignant Tumors.
Conditions
- Advanced Malignant Tumors
Interventions
LBL-007 InjectionDrug
LBL-007 Injection; dose A or dose B; Q3W
Toripalimab InjectionDrug
Toripalimab Injection; dose C; Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30+7 days after drug withdrawal or before the start of new anti-tumor therapy)
- Dose-limiting toxicities(DLT)Time frame: During the first Cycles(each cycle is 21 days)
- Maximum tolerated dose (MTD)Time frame: During the first Cycles(each cycle is 21 days)
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
The first affiliated hospital of bengbu medical University
Bengbu, Anhui, China
Chongqing University Three gorges Hospital
Chongqing, Chongqing Municipality, China
The 900 Hospital of the Joint Service Support Force of the People's Liberation Army of China
Fuzhou, Fujian, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
The First People's Hospital of Yu Lin
Yulin, Guangxi, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
Hubei Cancer Hospital
Wuhan, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
Changzhou Cancer Hospital
Changzhou, Jiangsu, China
Qilu Hospital of Shandong University
Jinan, Shandong, China
Affiliated Hospital of Jining Medical University
Jining, Shandong, China
Linyi Cancer Hospital
Linyi, Shandong, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.